<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823403</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003766-40</org_study_id>
    <secondary_id>2020/3138</secondary_id>
    <nct_id>NCT04823403</nct_id>
  </id_info>
  <brief_title>Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>HIPANIV</acronym>
  <official_title>A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the Maximum Tolerated Dose (MTD), and the recommended Phase 2 dose of HIA&#xD;
      Ipilimumab in combination with IV Nivolumab by monitoring the Dose Limiting Toxicity (DLT)&#xD;
      within 1 month after IA Ipilimumab administration in dose-escalation phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1, Dose-Escalation (3+3 design), Open-label, single arm, single-center study, and expansion cohort. DLT will be captured within 1 month after HIA administration.&#xD;
3 levels of dose of HIA ipilimumab will be tested. Starting by a dose 5 times lower than what is used for IV administration.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the Maximum Tolerated Dose (MTD), and the recommended Phase 2 dose of HIA Ipilimumab in combination with IV Nivolumab by monitoring the Dose Limiting Toxicity (DLT) within 1 month after IA Ipilimumab administration in dose-escalation phase.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with heptaocellular carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.&#xD;
Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.&#xD;
(D1) Starting dose : 50 mg; n=3 to 6&#xD;
(D2) 2nd dose-level : 100 mg; n=3 to 6&#xD;
(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (&gt;1/3 DLT at D1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.</description>
    <arm_group_label>Patients with heptaocellular carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.&#xD;
(D1) Starting dose : 50 mg; n=3 to 6&#xD;
(D2) 2nd dose-level : 100 mg; n=3 to 6&#xD;
(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (&gt;1/3 DLT at D1)</description>
    <arm_group_label>Patients with heptaocellular carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult Men and women ≥ 18 years old&#xD;
&#xD;
          2. Patient should understand, sign, and date the written informed consent form prior to&#xD;
             any protocol-specific procedures performed.&#xD;
&#xD;
          3. Patient should be able to comply with treatment, PK, and pharmacodynamic sample&#xD;
             collection and willing to comply with study visits and procedures as per protocol.&#xD;
&#xD;
          4. Patients must have pathological confirmation of HCC.&#xD;
&#xD;
          5. Patient should be considered as non resectable by Multidisciplinary Team and liver&#xD;
             surgeon, and non-eligible for liver transplantation (advanced HCC, BCLC C).&#xD;
&#xD;
          6. Patient who progresses on, or is intolerant to, or has refused standard first line&#xD;
             therapy and eligible for receiving IV infusion of Nivolumab and HIA administration of&#xD;
             Ipilimumab&#xD;
&#xD;
          7. Patient with active intrahepatic HCC. Part of the disease should not have undergone&#xD;
             local treatments (including chemoembolization, or percutaneous targeted therapies).&#xD;
&#xD;
          8. Patients with or without active viral infection (i.e., HCV, HBV) are eligible.&#xD;
             Patients with active HBV/HCV are eligible provided they are adequately treated to&#xD;
             control the disease.&#xD;
&#xD;
          9. Patients should have measurable disease as defined by mRECIST criteria for response&#xD;
             assessment.&#xD;
&#xD;
         10. ECOG status of 0 or 1 (Appendix 2).&#xD;
&#xD;
         11. Life expectancy of ≥ 12 weeks at the time of informed consent per Investigator&#xD;
             assessment.&#xD;
&#xD;
         12. Adequate organ function as defined by the following:&#xD;
&#xD;
               1. White blood cells (WBCs) ≥ 2000/mL&#xD;
&#xD;
               2. Neutrophils ≥ 1000/mL&#xD;
&#xD;
               3. Platelets ≥ 75 × 103/mL&#xD;
&#xD;
               4. Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
               5. Creatinine &lt; 1.5 × ULN or creatinine clearance ≥ 40mL/min (Cockcroft-Gault&#xD;
                  formula)&#xD;
&#xD;
               6. ALT and AST ≤ 3 × ULN&#xD;
&#xD;
               7. Lipase and amylase ≤ 1.5 × ULN&#xD;
&#xD;
               8. Total bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
               9. Normal thyroid function, or stable on hormone supplementation per investigator&#xD;
                  assessment&#xD;
&#xD;
         13. Child-Pugh A, Without history of encephalopathy or clinically significant ascites&#xD;
&#xD;
         14. Women of childbearing potential (WOCBP) must have a negative urine or serum β-HCG&#xD;
             pregnancy test within 14 days prior inclusion. If the urine test is positive or cannot&#xD;
             be confirmed as negative, a serum pregnancy test will be required. Sexually active&#xD;
             female patients must agree to use two methods of effective contraception, one of them&#xD;
             being a barrier method, or to abstain from sexual activity during the study and for at&#xD;
             least 5 months after last study drug administration or must refrain from heterosexual&#xD;
             activity during this same period.&#xD;
&#xD;
         15. Sexually active males patients must agree to use condom during the study and for at&#xD;
             least 7 months after the last study treatment administration. Also, it is recommended&#xD;
             their women of childbearing potential partner use a highly effective method of&#xD;
             contraception for the same duration.&#xD;
&#xD;
         16. Patients shall be eligible to undergo pre-treatment and on-treatment tumor biopsies.&#xD;
             Patients who either do not consent to a pre-treatment tumor biopsy or do not have&#xD;
             accessible lesions will not be eligible.&#xD;
&#xD;
         17. Resolved acute effects of any prior therapy to baseline severity or NCI CTCAE v5 Grade&#xD;
             ≤1 except for AEs not constituting a safety risk by investigator judgment.&#xD;
&#xD;
         18. Patients must be affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a prior malignancy are excluded, except those with prior malignancies&#xD;
             treated more than 2 years previously (at the time of informed consent) with curative&#xD;
             intent with no evidence of disease during the interval and who are considered by the&#xD;
             Investigator to present a low risk for recurrence, will be eligible.&#xD;
&#xD;
          2. Patients with any active autoimmune disease or history of known or suspected&#xD;
             autoimmune disease with the exception of patients with vitiligo, resolved/controlled&#xD;
             asthma/atopy, controlled hypoadrenalism or hypopituitarism, and euthyroid patients&#xD;
             with a history of Grave-Basedow&quot;s disease (patients with controlled hyperthyroidism&#xD;
             must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid&#xD;
             stimulating immunoglobulin prior to inclusion).&#xD;
&#xD;
          3. A known or underlying medical condition that, in the opinion of the Investigator,&#xD;
             could make the administration of study drug hazardous to the subject or could&#xD;
             adversely affect the ability of the subject to comply with or tolerate study.&#xD;
&#xD;
          4. Requirement for daily supplemental oxygen&#xD;
&#xD;
          5. Any of the following within the 6 months prior to study entry: myocardial infarction,&#xD;
             uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive&#xD;
             heart failure, cerebrovascular accident or transient ischemic attack.&#xD;
&#xD;
          6. A confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year&#xD;
             prior to informed consent.&#xD;
&#xD;
          7. Positive blood screen for human immunodeficiency virus (HIV) with acquired&#xD;
             immunodeficiency syndrome (AIDS). Patients with controlled HIV infection under&#xD;
             anti-retroviral therapy and normal CD4+ T-cell counts (&gt;500/mm3) could be considered&#xD;
             eligible by the investigator if the patient fulfills the other inclusion/exclusion&#xD;
             criteria.&#xD;
&#xD;
          8. Evidence of active infection that requires systemic antibacterial, antiviral, or&#xD;
             antifungal therapy ≤ 7 days prior to inclusion.&#xD;
&#xD;
          9. Any other significant acute or chronic medical illness. Any other sound medical,&#xD;
             psychiatric, and/or social reason as determined by the Investigator.&#xD;
&#xD;
         10. Subjects who are unable to undergo and/or tolerate venous AND arterial access&#xD;
             (evaluated on pre-treatment imaging)&#xD;
&#xD;
         11. Systemic or topical corticosteroids at immunosuppressive doses (≥ 10 mg/day of&#xD;
             prednisone or equivalent)&#xD;
&#xD;
         12. Patients that have received within 4 weeks or 5 half-lives (whichever is shorter) from&#xD;
             inclusion and who are planned to receive the following during treatment:&#xD;
&#xD;
               1. Any other investigational drug&#xD;
&#xD;
               2. Any anticancer therapy (chemotherapy, biologics, therapeutic vaccines,&#xD;
                  radiotherapy, or hormonal treatment).&#xD;
&#xD;
               3. Vaccines containing live virus&#xD;
&#xD;
               4. Allergen hyposensitization therapy&#xD;
&#xD;
               5. Growth factors, e.g., granulocyte-colony stimulating factor (G-CSF), granulocyte&#xD;
                  macrophage-colony stimulating factor (GM-CSF), erythropoietin&#xD;
&#xD;
               6. Major surgery&#xD;
&#xD;
               7. Bisphosphonates or anti-RANKL therapy&#xD;
&#xD;
         13. Previous allogeneic hematopoietic stem cell transplantation or pprevious solid organ&#xD;
             transplantation requiring systemic immunosuppressive therapy&#xD;
&#xD;
         14. History of severe allergy, anaphylactic or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or to biopharmaceutical produced in Chinese hamster&#xD;
             ovarian cells or to any components of the study drugs&#xD;
&#xD;
         15. Patients with an active pneumonitis or a history of grade 3 or 4 pneumonitis due to&#xD;
             the administration of immunotherapies.&#xD;
&#xD;
         16. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
&#xD;
         17. Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lambros Tselikas, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>lambros.tselikas@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thibault RAOULT</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>thibault.raoult@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lambros Tselikas, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>lambros.tselikas@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

